Literature DB >> 24656177

Incidence of hypercoagulable events after image-guided percutaneous cryoablation of renal tumors: a single-center experience.

Jason B Hartman1, Nicholas Bhojwani2, David J Corn2, Matthew M Cooney3, John Haaga2, Lee Ponsky4, Robert Abouassaly4, Akshay Paspulati5, J David Prologo6.   

Abstract

PURPOSE: To identify retrospectively hypercoagulable events that occurred over time in patients who underwent image-guided percutaneous renal cryoablation and compare the incidence with a cohort of patients who underwent surgical partial nephrectomy (PN) during the same time period.
MATERIALS AND METHODS: An electronic medical record database was queried for patients who underwent percutaneous image-guided renal mass cryoablation or PN between September 2006 and June 2012. Records were examined for thrombotic events during the year following the procedure in each group. Incidence rates, Kaplan-Meier estimates, and patient demographic variables were compared using the stratified log-rank test and t test for independent samples.
RESULTS: The study comprised 114 cryoablation cases. The cumulative incidence of thrombotic events after 1 year was 4.39%. The incidence per 100 person-years was 4.84. There were 105 PN cases. The cumulative incidence of thrombotic events after 1 year was 1.0%. The incidence per 100 person-years was 1.14. The person-time incidence rate difference for these two groups did not reach statistical significance (P = .0894).
CONCLUSIONS: The incidence of thrombotic events in patients who underwent percutaneous renal cryoablation in this study was not significantly different than a comparable cohort who underwent surgical PN during the same time period.
Copyright © 2014 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24656177      PMCID: PMC3995864          DOI: 10.1016/j.jvir.2014.01.027

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  25 in total

1.  Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.

Authors:  Hyun J Bang; Peter J Littrup; Dylan J Goodrich; Brandt P Currier; Hussein D Aoun; Lance K Heilbrun; Ulka Vaishampayan; Barbara Adam; Allen C Goodman
Journal:  J Vasc Interv Radiol       Date:  2012-04-25       Impact factor: 3.464

2.  Reporting standards for percutaneous thermal ablation of renal cell carcinoma.

Authors:  Timothy W I Clark; Steven F Millward; Debra A Gervais; S Nahum Goldberg; Clement J Grassi; Thomas B Kinney; David A Phillips; David Sacks; John F Cardella
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

3.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

Authors:  N Levitan; A Dowlati; S C Remick; H I Tahsildar; L D Sivinski; R Beyth; A A Rimm
Journal:  Medicine (Baltimore)       Date:  1999-09       Impact factor: 1.889

4.  Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.

Authors:  Martijn H M G M den Brok; Roger P M Sutmuller; Stefan Nierkens; Erik J Bennink; Liza W J Toonen; Carl G Figdor; Theo J M Ruers; Gosse J Adema
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

Review 5.  Ablative therapies for small renal tumours.

Authors:  Arturo Castro; Lawrence C Jenkins; Nelson Salas; Gideon Lorber; Raymond J Leveillee
Journal:  Nat Rev Urol       Date:  2013-04-23       Impact factor: 14.432

Review 6.  Venous thromboembolism and cancer: risks and outcomes.

Authors:  Agnes Y Y Lee; Mark N Levine
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

Review 7.  Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies.

Authors:  Gianpiero Gravante; Giuseppe Sconocchia; Seok Ling Ong; Ashley R Dennison; David M Lloyd
Journal:  Liver Int       Date:  2008-10-30       Impact factor: 5.828

8.  Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome.

Authors:  Thomas D Atwell; Michael A Farrell; Matthew R Callstrom; J William Charboneau; Bradley C Leibovich; Igor Frank; David E Patterson
Journal:  AJR Am J Roentgenol       Date:  2007-05       Impact factor: 3.959

9.  Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma.

Authors:  Yongping Yang; Chunping Wang; Yinying Lu; Wenlin Bai; Linjing An; Jianhui Qu; Xudong Gao; Yan Chen; Lin Zhou; Yu Wu; Yongyi Feng; Minna Zhang; Xiujuan Chang; Jiyun Lv
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-11       Impact factor: 7.027

10.  Pulmonary thromboembolism after renal laparoscopic cryoablation: a case report.

Authors:  Anuar Ibrahim Mitre; Rafael Ferreira Coelho; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

View more
  2 in total

1.  Percutaneous CT-guided cryoablation for the treatment of refractory pudendal neuralgia.

Authors:  J David Prologo; Roger C Lin; Roger Williams; David Corn
Journal:  Skeletal Radiol       Date:  2014-12-17       Impact factor: 2.199

2.  Transperineal cryotherapy for unresectable muscle invasive bladder cancer: preliminary experience with 7 male patients.

Authors:  Qing Zhang; Shiwei Zhang; Shun Zhang; Wei Wang; Xiaozhi Zhao; Yongming Deng; Huibo Lian; Hongqian Guo
Journal:  BMC Urol       Date:  2017-09-09       Impact factor: 2.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.